AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03770299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Specified dose on specified days
Study NCT06197906 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Device implant
Description: subcutaneous device implanting
Study NCT05977894 — intervention group
Intervention type: OTHER
Intervention: Reduced Environmental Stimulation Therapy
Description: During floatation-REST (Reduced Environmental Stimulation Therapy), the participant enters a tank that is approximately 5 feet wide, 7 feet long and 5 feet high. The tank is filled with a 10 inch height of water containing enough Epsom salt (magnesium sulfate) to create body buoyancy. The water temperature is 93.5 degrees F, an approximate equivalent for normal skin temperature. Ear plugs are used to mitigate sound and the tank is without light illumination to prevent visual stimulation. The sessions are typically 60 minutes in duration. The individual is Floating-in Solitude, Darkness, Silence, and Thermal-Neutrality. This experience reduces external sensory nervous system input and creates an extraordinarily deep state of mental and physical relaxation.
Study NCT05276167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperthermic intravesical perfusion
Description: Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
Study NCT05282290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (no restriction on the type of drugs)
Description: The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening.
Study NCT05282290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive drugs (no restriction on the type of drugs)
Description: The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening.
Study NCT05263297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: no intervention will be made.
Study NCT06483425 — intervention group
Intervention type: GENETIC
Intervention: Sequencing of DNA, RNA, and Proteins
Description: Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
Study NCT03770299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Specified dose on specified days
Study NCT06425848 — intervention group
Intervention type: DEVICE
Intervention: Observational
Description: We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.
Study NCT03770299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days
Study NCT03770299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Specified dose on specified days
Study NCT03770299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days
Study NCT03770299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days
Study NCT05809674 — intervention group
Intervention type: DEVICE
Intervention: Polarization sensitive optical coherence tomography (PS-OCT)
Description: The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
Study NCT06472336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracranial stenting
Description: Intracranial stenting (+/- balloon dilatation) will be performed. Decisions regarding intracranial stenting are solely made by the treating physician. This means in specific, that the treating physician decides based on his/her judgement or based on local standards (as reported in the literature) on the devices and/or concomitant medications (including infusion/administration of antiplatelet medicine) used for intracranial stenting.
Study NCT06472336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of conventional endovascular therapy (EVT)
Description: Patients undergo either (a) continued stent retriever or contact aspiration based endovascular treatment manoeuvres, (b) infusion/administration of antiplatelet medication or (c) stop of the procedure depending on local standard treatment approaches.
Study NCT05802186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05802186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05802186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05802186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05802186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiology, Treatment Planning
Description: Undergo radiation planning with AI-directed analysis for dose recommendation
Study NCT05802186 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT05802186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study NCT05586464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ban xia xie xin Decoction and bismuth quadruplicate group
Description: Ban xia xie xin Decoction:10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
Study NCT05586464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth quadruplicate group
Description: Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
Study NCT05249062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAPES app
Description: Participants will be asked to use the app and connected devices daily for 3 months.
Study NCT05683717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-01488 Tablets
Description: TT-01488 tablet will be administered orally once daily per protocol defined schedule.
Study NCT04895514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma-irradiated corneal tissue inlay
Description: A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of gamma-irradiated preserved corneal tissue will then be placed into the pocket
Study NCT03770299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT05412810 — intervention group
Intervention type: OTHER
Intervention: oxygen
Description: oxygen exposure of more than 50% for 1.5 hours
Study NCT05047263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: Tablet, 10 mg or 20 mg, once daily (OD), oral
Study NCT05047263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily, oral
Study NCT05268081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual specialist conferences
Description: The intervention consists of four virtual conferences (45 min each in month 2, 5, 8 and 11) and an introductory webinar (90 min in month 1) to learn GPs about how to use the electronic Diabetes Overview to identify and manage patients with T2D. Each general practice is assigned to one specific endocrinologist they meet with throughout. The four virtual conferences are thematic: T2D and cardiovascular disease and heart failure, T2D and lipids, T2D and kidney disease and blood pressure, and T2D and a free topic selected by the GP. At each conference, the GP must bring 2-3 patient cases related to the theme and 1-2 patients of their own choice. The GP chairs the meeting. Each conference follows the same format: Check in (5 min); Short presentation by the endocrinologist (10 min); Presentation by GP and joint dialogue about theme-related patients (20 min); Presentation by GP and joint dialogue about theme-unrelated patients (optional, 5 min); (5) Wrapping-up (5 min).
Study NCT06384612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use of pocket cards
Description: Use of pocket cards of 22 cm x 11 cm size prepared by students every week in classes
Study NCT06626113 — intervention group
Intervention type: DRUG
Intervention: ascorbic acid
Description: ascorbic acid
Study NCT06624553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre 2, flash glucose monitoring
Description: Currently, at the Hospital de la Santa Creu i Sant Pau, when starting monitoring in people with DM2, capillary glycemia monitoring is used, following the therapeutic education protocols in basal insulinization in the debut of DM2 and in optimization of treatment, protocols that are also applied to similar cases.~The intervention group (FreeStyle Libre 2) will be provided with the necessary material to carry out the monitoring via a glucose sensor. Satisfaction with treatment will be assessed at the final study visit.
Study NCT06624761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: A randomized study investigating ShotBlocker in painkillers containing different active ingredients could not be found.
Study NCT05718687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT021601
Description: Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
Study NCT06413355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]-FAPI-74
Description: A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).
Study NCT06759779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: Inspiratory muscle training will be performed
Study NCT06759779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: expiratory muscle training
Description: Expiratory muscle training will be performed
Study NCT06763796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postural Decryption Technique
Description: Assessment:~PDT begins with visual inspection and palpation to check postural alignment and identify joint or muscle imbalances. Evaluations proceed distal to proximal, examining the spine and shoulder complex in coronal, sagittal, and transverse planes to assess symmetry and neutral positioning.~Treatment Process:~PDT applies the 4R Technique:~1. Reposition - Correct joint alignment.~2. Restore - Release muscle tension and adhesions.~3. Reinforce - Strengthen stabilizing muscles.~4. Retrain - Improve movement patterns and posture.~Key Techniques:~1. Spinal and Shoulder Adjustments: Manual traction, mobilizations, and stretches.~2. Joint Mobilization: Multi-directional gliding within pain-free ranges.~3. Trigger Point Therapy: 5-10 seconds of pressure to relieve localized pain.~4. Proprioception Training: Balance challenges to improve stability and control.
Study NCT06763796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Medicine (TCM) Massage Therapy
Description: Definition:~A manual therapy based on Traditional Chinese Medicine (TCM) principles, using techniques like kneading, pressing, rolling, and stretching to relieve pain, improve circulation, and enhance mobility.~Key Features:~1. Techniques: Soft tissue manipulation, joint mobilization, and acupressure.~2. Focus: Pain relief, joint function recovery, and muscle relaxation.~Treatment Plan:~4 weeks, 5 sessions per week, 40 minutes per session.
Study NCT06763809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PMS Capsule
Description: Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Study NCT06763809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsule Placebo
Description: Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Study NCT06763809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PMS Gummy
Description: Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Study NCT06763809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gummy Placebo
Description: Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Study NCT06763744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Y12 antagonist monotherapy
Description: CYP2C19 genetic testing is performed before discharge after stent insertion. Depending on the test results, rapid (CYP2C19\*1/\*17 or \*17/\*17) or normal (CYP2C19\*1/\*1) metabolizers are treated with clopidogrel monotherapy, and intermediate or poor metabolizers (with CYP2C19\*2 or \*3 alleles) are treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) monotherapy.
Study NCT06763744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel + aspirin
Description: In this group, a potent P2Y12 inhibitor was changed to clopidogrel (un-guided) 1 month after PCI with maintenance of co-prescription of aspirin (DAPT).
Study NCT06764433 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: GONPRF
Description: GON PRF treatment, which we apply by imaging the target nerve and surrounding structures with the proximal technique (at C2 level) under USG guidance in patients who do not respond to conservative treatments for cervicogenic headache.
Study NCT06764433 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proximal GONPRF
Description: Ultrasound-guided pulsed radiofrequency treatment of the greater occipital nerve at the C2 level
Study NCT06764654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant placement
Description: Placement of two dental implants in the jaw.
Study NCT06764654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement
Description: Placement of two dental implants in the jaw.
Study NCT04594642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486 IV
Description: AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
Study NCT06009601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pectus Study Form
Description: Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.~In addition, this study form includes 'Quality of Life Evaluation Form in Pectus Deformity', 'Social Comparison Scale', 'Sleep Disorder Scale for Children', 'Anxiety Disorders Screening Scale in Children', 'Pediatric Quality of Life Questionnaire' designed for patients and their relatives. PedsQL)', 'SRS-22 Patient Questionnaire', 'Beck Anxiety Scale' and 'Informed Consent Form' designed for patients and their relatives.
Study NCT06009601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adams Test
Description: Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 7 degrees in patients who meet the inclusion criteria will be included in the study by filling out an informed consent form
Study NCT06009601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scoliosis Graphy
Description: ATR (angle of trunk rotation) values above 7 degrees on bunnell scoliometer were determined. Afterwards, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis graphy will be requested.~Coronal, sagittal balance; coronal and sagittal cobb angles will be measured from posterior-anterior (PA) (posterior-anterior) and lateral (lateral) scoliosis radiographs.
Study NCT06009601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~There are 2 types of disorders that cause problems with air moving in and out of the lungs:~Obstructive. This is when air has trouble flowing out of the lungs due to airway resistance. This causes a decreased flow of air.~Restrictive. This is when the lung tissue and/or chest muscles can't expand enough. This creates problems with air flow, mostly due to lower lung volumes.
Study NCT05115344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 25mg
Description: 1 case,The starting dose,Take the medicine once on D1,D 5-21.
Study NCT05115344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 50mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study NCT05115344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 100mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study NCT05115344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 150mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study NCT05115344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 225mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study NCT05115344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flonoltinib 325mg
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study NCT06207799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Given by SC
Study NCT06207799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by PO
Study NCT06207799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given by SC
Study NCT06207799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given by IV
Study NCT06207799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given by PO
Study NCT06207799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given by IV
Study NCT06207799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Given by IV
Study NCT05054309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium longum
Description: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
Study NCT05054309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum
Description: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
Study NCT04882098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab as SC injection.
Study NCT04882098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.
Study NCT04945330 — intervention group
Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Follow clinical practice
Study NCT06470074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: Transcranial electrical stimulation can modulate the brain functional network through weak transcranial current
Study NCT06470074 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: Transcranial electrical stimulation can modulate the brain functional network through weak transcranial current
Study NCT06247202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Phone Education (mhealth)
Description: Nutrition and Health Education module delivered through m-health approach (smart phones)
Study NCT06247202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Education (conventional)
Description: Nutrition and Health Education module delivered through conventional approach (paper)
Study NCT06434714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular percutaneous nerve field stimulator
Description: Percutaneous nerve field stimulator device placed on the ear for 5 days